Skip to main content

Botulinum Toxin

No sources yet

An index of captured practitioner sources, not a completed evidence summary. Unchecked figures and empty sections are omitted. See the library review status.

Source summary generated November 6, 2026; this date does not indicate completed review.

Tissue researchAliases: Botox, onabotulinumtoxinA
Track your own protocol free →

Quotes from three independent practitioners, with their sources. Research context only.

What it is and how it works

From the published literature on Botulinum Toxin; the papers are listed at the end. Research summary, not a recommendation.

What it is

Botulinum toxin is a large protein (a neurotoxin) made by the bacterium Clostridium botulinum; it exists in seven types, A to G, and type A is the basis of most medicines. Purified, licensed preparations of type A, such as onabotulinumtoxinA (Botox and Botox Cosmetic), abobotulinumtoxinA, incobotulinumtoxinA, prabotulinumtoxinA and daxibotulinumtoxinA, are FDA-approved biologic medicines given by injection. The products are measured in brand-specific units that are not interchangeable between brands.

How it works

Nerves tell muscles to contract, and sweat glands to secrete, by releasing the chemical messenger acetylcholine at their endings. Botulinum toxin binds to these nerve endings, is taken inside, and its active part cuts a protein called SNAP-25 that the nerve needs to release acetylcholine; type A removes nine amino acids from the end of SNAP-25, which disables it. The injected muscle therefore weakens and relaxes, and treated sweat glands produce less sweat, until the nerve ending remodels and recovers over a period of months, which is why treatment wears off. Reviews also describe blocking of pain-signalling chemicals released from sensory nerves, which is the proposed basis of its use in chronic migraine.

What it has been studied for

  • Frown lines between the eyebrows (glabellar lines) and other cosmetic facial lines (network meta-analysis of randomized trials)
  • Prevention of chronic migraine (pooled phase 3 randomized trials)
  • Arm spasticity after stroke (systematic review and meta-analysis of randomized trials)
  • Excessive underarm sweating (primary axillary hyperhidrosis) (meta-analysis of randomized trials)
  • Illness after counterfeit or mishandled cosmetic injections (CDC outbreak report)

Strength of the evidence

Approved drugSeveral botulinum toxin type A products are FDA-approved biologics for cosmetic lines, chronic migraine, spasticity, underarm sweating and other conditions, supported by large placebo-controlled randomized trials and meta-analyses.

What the literature reports on safety

All botulinum toxin products carry an FDA boxed warning on distant spread of toxin effect: the toxin's effects can spread beyond the injection site hours to weeks later and cause botulism-like symptoms such as general weakness, double or blurred vision, drooping eyelids and trouble swallowing, speaking or breathing, and swallowing and breathing problems can be life threatening, with deaths reported. In the pooled chronic migraine trials adverse events were mostly mild to moderate and few people stopped treatment because of them. In 2024 the CDC reported clusters of 22 people in 11 states who became ill after injections from unlicensed or untrained people or in non-healthcare settings such as homes and spas, mostly for cosmetic purposes; 11 were hospitalized and 6 received botulism antitoxin, and in one investigated cluster the FDA found the product was counterfeit.

Key papers

  1. The structure and mode of action of different botulinum toxins. (opens in a new tab)

    Review · Dolly JO, Aoki KR · European Journal of Neurology (2006) · PMID 17112344

    Described how the toxin binds nerve endings, enters them and cleaves SNAP-25 to block acetylcholine release, and attributed its long duration to the persistence of the toxin's enzyme and of cleaved SNAP-25 and to slow remodelling of the nerve-muscle junction.

  2. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. (opens in a new tab)

    Randomized trial · Dodick DW, Turkel CC, et al. · Headache (2010) · PMID 20487038

    Across two pooled phase 3 trials in 1384 adults, onabotulinumtoxinA reduced headache days significantly more than placebo at 24 weeks; adverse events occurred in 62.4% versus 51.7% on placebo, mostly mild to moderate.

  3. Efficacy and Safety of Botulinum Toxin Type A for Treatment of Glabellar Lines: A Network Meta-Analysis of Randomized Controlled Trials. (opens in a new tab)

    Review · Li X, Sui C, et al. · Aesthetic Plastic Surgery (2023) · PMID 36097079

    Compared five type A preparations for frown lines and found all far superior to placebo, with no significant differences in adverse events between preparations.

  4. Effectiveness of Botulinum Toxin Treatment for Upper Limb Spasticity Poststroke Over Different ICF Domains: A Systematic Review and Meta-Analysis. (opens in a new tab)

    Review · Andringa A, van de Port I, et al. · Archives of Physical Medicine and Rehabilitation (2019) · PMID 30796921

    Across 40 randomized trials with 2718 stroke patients, the toxin robustly reduced muscle stiffness and improved self-care of the affected arm, but did not improve active arm and hand capacity.

  5. Efficacy and Safety of Botulinum Toxin Type A in Primary Axillary Hyperhidrosis: A Meta-analysis and Systematic Review. (opens in a new tab)

    Review · Sun J, Chen S, et al. · Aesthetic Plastic Surgery (2025) · PMID 40500510

    Across 12 randomized trials with 904 participants, type A injections reduced underarm sweating significantly more than placebo and performed similarly to other treatments with fewer side effects.

  6. Notes from the Field: Illnesses After Administration of Presumed Counterfeit Botulinum Toxin in Nonmedical Settings - Tennessee and New York City, March 2024. (opens in a new tab)

    Case series · Thomas CM, McElroy R, et al. · MMWR Morbidity and Mortality Weekly Report (2024) · PMID 38990782

    Seven women became ill with drooping eyelids, dry mouth, trouble swallowing, shortness of breath and weakness after cosmetic injections given by unlicensed people in homes or a spa; four were hospitalized, and the FDA found the product used in one cluster was counterfeit.

Sources checked: PubMed (E-utilities esummary and abstracts on every PMID), CDC MMWR full text (cdc.gov/mmwr mm7327a3), CDC Health Alert Network advisory CDCHAN-00507 (April 23, 2024), BOTOX and BOTOX Cosmetic prescribing information boxed warning (DailyMed, accessdata.fda.gov), written 2026-11-06.

No sources yet

None of the three teachers' sources we have indexed discuss Botulinum Toxin yet. This page will fill in as sources are added.

Deeper guided audio lives on What Am I Appreciating Now (leaves this site, opens in a new tab). What Am I Appreciating Now is a separate site run by the same operator; it sells meditation and hypnosis sessions.

Disclaimer: for research purposes only

All content on this page is for research and educational purposes only and is not intended as medical advice. Always consult a qualified healthcare provider before starting any peptide or hormone protocol. You take responsibility for your own protocol.If your path includes peptides, you buy them yourself from an independent licensed provider through a member co-op; we take nothing. How independent access works.

Botulinum Toxin — Hunter, Taylor, Bachmeyer | Reset Biology